MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

Getty ImagesWith around 5% of COVID-19 patients estimated to develop long COVID, it remains a global health issue.To help ...

Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and ...

This study investigates the impact of myenteric neuron-macrophage interactions on postoperative trauma and subsequent ...

Diplomas and Certifications Top Doc Award Dr. Pamela Cipriano, Nurse Practitioner Natural Nutmeg 10 Best Award Dr. Pamela Cipri ...

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

CK-0802 is under clinical development by Cellenkos and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Mesenchymal Stem Cells-Derived Exosomes is under clinical development by AbelZeta and currently in Phase II for Acute Respiratory Distress Syndrome.